Archford Capital Strategies’s Abiomed Inc ABMD Stock Holding History

Archford Capital Strategies’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-360	Closed	-$94K	–	541
2019 Q2	$94K	Sell	360 -40	-10%	-$10.6K	0.03%	243
2019 Q1	$114K	Hold	400	–	–	0.04%	235
2018 Q4	$130K	Hold	400	–	–	0.05%	217
2018 Q3	$180K	Hold	400	–	–	0.07%	209
2018 Q2	$164K	Hold	400	–	–	0.06%	215
2018 Q1	$75K	Buy	+400	New	+$101K	0.03%	182
2017 Q2	–	Sell	-400	Closed	-$50K	–	663
2017 Q1	$50K	Buy	+400	New	+$46.4K	0.02%	287
2016 Q4	–	Sell	-400	Closed	-$51K	–	765
2016 Q3	$51K	Hold	400	–	–	0.02%	262
2016 Q2	$44K	Buy	+400	New	+$39.8K	0.02%	261
2016 Q1	–	Sell	-400	Closed	-$37K	–	645
2015 Q4	$37K	Hold	400	–	–	0.02%	292
2015 Q3	$37K	Hold	400	–	–	0.03%	212
2015 Q2	$26K	Hold	400	–	–	0.02%	247
2015 Q1	$28.6K	Hold	400	–	–	0.02%	253
2014 Q4	$15K	Hold	400	–	–	0.01%	321
2014 Q3	$10K	Hold	400	–	–	0.01%	352
2014 Q2	$10.1K	Hold	400	–	–	0.01%	407
2014 Q1	$10.4K	Buy	+400	New	+$11.1K	0.01%	414

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Archford Capital Strategies's ABMD Position: Q3 2019 in Review

Archford Capital Strategies sold out of Abiomed Inc (ABMD) in Q3 2019, closing a stake of 360 shares — an estimated $94K sold.

Archford Capital Strategies first reported a position in ABMD in Q1 2014 and held it in 17 quarters. The position peaked at $180K in Q3 2018. 443 funds tracked by Wall St. Rank hold ABMD as of Q3 2019.

Archford Capital Strategies reported no remaining Abiomed Inc position as of Q3 2019 after selling out during the quarter.
Archford Capital Strategies sold 360 Abiomed Inc shares in Q3 2019, an estimated $94K.
Archford Capital Strategies first reported a position in Abiomed Inc in Q1 2014 and held it in 17 quarters.
Archford Capital Strategies's Abiomed Inc position peaked at $180K in Q3 2018.
443 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2019.

Based on Archford Capital Strategies's 13F filing for Q3 2019, filed 23 Oct 2019.